Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2.
作者信息
Huang Baoying, Dai Lianpan, Wang Hui, Hu Zhongyu, Yang Xiaoming, Tan Wenjie, Gao George F
机构信息
NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
出版信息
Lancet Microbe. 2021 Jul;2(7):e285. doi: 10.1016/S2666-5247(21)00082-3. Epub 2021 Apr 13.
Abstract
摘要
相似文献
1
Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2.
Lancet Microbe. 2021 Jul;2(7):e285. doi: 10.1016/S2666-5247(21)00082-3. Epub 2021 Apr 13.
2
Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
J Clin Virol. 2022 Jun;150-151:105161. doi: 10.1016/j.jcv.2022.105161. Epub 2022 Apr 12.
3
Neutralization of SARS-CoV-2 omicron after BBIBP-CorV and ZF2001 booster vaccination.
Travel Med Infect Dis. 2023 Mar-Apr;52:102531. doi: 10.1016/j.tmaid.2022.102531. Epub 2022 Dec 19.
4
Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Front Immunol. 2022 Sep 9;13:967051. doi: 10.3389/fimmu.2022.967051. eCollection 2022.
5
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
Geroscience. 2021 Oct;43(5):2321-2331. doi: 10.1007/s11357-021-00471-6. Epub 2021 Oct 11.
6
Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Vaccine. 2022 Sep 16;40(39):5701-5708. doi: 10.1016/j.vaccine.2022.08.037. Epub 2022 Aug 22.
7
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
Mol Immunol. 2022 Mar;143:94-99. doi: 10.1016/j.molimm.2022.01.009. Epub 2022 Jan 17.
8
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Genome Med. 2022 Dec 29;14(1):146. doi: 10.1186/s13073-022-01151-6.
9
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
BMC Public Health. 2022 Aug 20;22(1):1584. doi: 10.1186/s12889-022-14016-9.
10
Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Eur Rev Med Pharmacol Sci. 2022 Jul;26(14):5297-5306. doi: 10.26355/eurrev_202207_29321.
引用本文的文献
1
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines.
Drugs. 2024 Apr;84(4):403-423. doi: 10.1007/s40265-024-02013-8. Epub 2024 Apr 23.
2
Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, and Heterologous Protection in Mice.
Vaccines (Basel). 2023 Sep 4;11(9):1453. doi: 10.3390/vaccines11091453.
3
A prospective observational study to evaluate the safety of COVID-19 mRNA vaccines administered to Qatar Rehabilitation Institute patients.
Qatar Med J. 2023 Mar 1;2023(1):10. doi: 10.5339/qmj.2023.10. eCollection 2023.
4
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines.
Prog Biophys Mol Biol. 2023 Mar;178:32-49. doi: 10.1016/j.pbiomolbio.2023.02.004. Epub 2023 Feb 18.
5
Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19.
Front Immunol. 2023 Jan 31;14:1118378. doi: 10.3389/fimmu.2023.1118378. eCollection 2023.
6
An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight.
Molecules. 2023 Jan 13;28(2):795. doi: 10.3390/molecules28020795.
7
Non-anticoagulant heparin derivatives for COVID-19 treatment.
Int J Biol Macromol. 2023 Jan 31;226:974-981. doi: 10.1016/j.ijbiomac.2022.12.090. Epub 2022 Dec 14.
8
COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan.
Cell Discov. 2022 Dec 9;8(1):131. doi: 10.1038/s41421-022-00496-x.
9
SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders.
Appl Biochem Biotechnol. 2023 Feb;195(2):1541-1573. doi: 10.1007/s12010-022-04181-3. Epub 2022 Oct 12.
10
Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines.
J Med Virol. 2023 Jan;95(1):e28172. doi: 10.1002/jmv.28172. Epub 2022 Oct 6.
本文引用的文献
1
A Case of New Variant COVID-19 First Emerging in South Africa Detected in a Security Guard at the Isolation Point - Shenzhen, China, January 23, 2021.
China CDC Wkly. 2021 Mar 5;3(10):218-220. doi: 10.46234/ccdcw2021.051.
2
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
3
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.
4
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Lancet Infect Dis. 2021 Jan;21(1):39-51. doi: 10.1016/S1473-3099(20)30831-8. Epub 2020 Oct 15.
5
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28.
Zotero 插件